WOUNDS article profiles efficacy of Quick-Med's antimicrobial BIOGUARD dressings

Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today that the February 2011 issue of WOUNDS, the leading peer-reviewed journal in the wound care field, will feature an article authored by Quick-Med's Albina Mikhaylova, PhD. The article profiles the safety and antimicrobial efficacy of cutting edge antimicrobial dressings employing Quick-Med's patented NIMBUS technology and marketed by Derma Sciences, Inc. (Nasdaq:DSCI) under its BIOGUARD^® trademark. Other Quick-Med authors include Bernd Liesenfeld, PhD, David Moore, BS, William Toreki, PhD, and Jill Vella, BS. Contributing authors from the University of Florida include professors Gregory Schultz, PhD, and Christopher Batich, PhD. Both Dr. Schultz and Dr. Batich are co-inventors of NIMBUS with Quick-Med.

The paper presents a preclinical evaluation of antimicrobial efficacy and biocompatibility of bacterial barrier dressings incorporating Quick-Med's proprietary NIMBUS technology. It notes that most bacterial barrier dressings in common usage today contain biocides that are released from the dressings and can be toxic to wound cells. The authors present the antimicrobial barrier properties of the novel BIOGUARD dressings and discuss how the underlying NIMBUS technology overcomes the significant limitations of antimicrobial technology currently used in wound dressings.

"The research confirms that BIOGUARD dressings safely demonstrate high performance against common wound pathogens without impeding healing", said Jerry Olderman, Vice President of Research and Development of Quick-Med Technologies. "The use of BIOGUARD dressings represents a new and significant way to augment the healing process because, as demonstrated in the study, while the active agent doesn't migrate into the wound it diminishes the bacterial load in the wound environment."

NIMBUS is the first non-leaching antimicrobial available in a bandage. It received U.S. Food and Drug Administration clearance in 2009. The bandages serve as a barrier to infection and kill germs such as MRSA and VRE. The antimicrobial does not leach into the wound to interfere with tissue healing. The NIMBUS active agent maintains effectiveness even in the presence of large amounts of proteinaceous exudates. By design, NIMBUS poses no risk of bacteria developing resistance.

The Company believes that being the only non-leaching antimicrobial bandage is an important distinction; silver and other antimicrobial dressings cost more and rely on the release of chemicals to the wound bed that can impede the wound healing process. NIMBUS technology is protected by nine U.S. patents and patents pending and 24 foreign counterparts.